5 Dumbest Things on...
Health Care: Drugs
Sucampo Pharmaceuticals Inc. A (SCMP: NASDAQ)
$8.85 0.23 | 2.67%
05/23/13 - 04:00 PM ET
Company Profile
| Price and Volume | |
|---|---|
| Recent Price | 8.85 |
| 52 Week High | 10.48 |
| 52 Week Low | 3.78 |
| Avg. Daily Vol. (Mil) | 0.28 |
| Beta (3 year) | 1.50 |
| Share Related Items | |
| Mkt Cap (Mil) | 371.40 |
| Shares Out (Mil) | 41.97 |
| Float (Mil) | 13.70 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 1.40 |
| Current Ratio | 2.10 |
| LT Debt/ Equity | 0.84 |
| Total Debt / Equity | 1.56 |
| Valuation Ratios | |
| Price Earnings | 98.30 |
| Price/Sales | 4.42 |
| Price/Book | 9.28 |
| Price/Cash Flow | 113.50 |
| Per Share Data | |
| Earnings | 0.09 |
| Sales | 2.00 |
| Book Value | 0.95 |
| Cash Flow | 0.08 |
| Business Summary | |
|---|---|
| A biopharmaceutical company focused on the discovery, development and commercialization of proprietary drugs based on prostones, a class of compounds derived from functional fatty acids that occur naturally in the human body. | |
| General Information | |
| 4520 East-West Highway
Suite 300 Bethesda, MD 20814 |
|
| www.sucampo.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 128 | |
| CEO: Dr. Ryuji Ueno,M.D. | |
| Short Interest | |
| Current Month (Mil) | 0.72 |
| Previous Month (Mil) | 0.56 |
| Short Interest Ratio (Days) | 2.10 |
| Management Effectiveness | |
| Return on Equity | 4.20 |
| Return on Assets | 1.30 |
| Return on Investments | 2.30 |
| Profitability | |
| Gross Margin | 75.40 |
| EBIT Margin | 9.10 |
| Profit Margin | 2.00 |
Portfolios with SCMP
- Portfolio NameUser Type
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Setting Up...
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Under-$10 Moving Hig...
- UserGFNN Stockdiagnostics 5
- User©SUPRATRADE HOT STOCKS (...
Latest SCMP Headlines from TheStreet
- Sucampo Pharmaceuticals Inc. A Stock Upgraded (SCMP) 04.18.13 | 05:04 am
- Most Profitable Second Quarter Biotech Stocks 04.02.13 | 06:04 am
- 5 Stocks Under $10 Triggering Breakouts 03.14.13 | 01:03 pm
- Best And Worst FDA Drug Approval Stocks of 2013 03.12.13 | 08:03 am
- Sucampo Pharmaceuticals Inc. A Stock Downgraded (SCMP) 03.12.13 | 05:03 am
- Play TheStreet's FDA Drug Approval Contest 03.05.13 | 12:03 pm
- TheStreet Ratings Top 10 Rating Changes 01.14.13 | 10:01 am
- Sucampo Pharmaceuticals Inc. A Stock Upgraded (SCMP) 01.14.13 | 04:01 am
- Sucampo Pharmaceuticals Inc. A Stock Upgraded (SCMP) 10.29.12 | 05:10 am
- 5 Stocks Poised for Breakouts 09.28.12 | 01:09 pm
Press Releases for SCMP
- Sucampo Pharmaceuticals, Inc. Reports Fourth Quarter And Full Year 2012 Financial And Operating Results - Business Wire 03.13.13 | 05:03 pm
- Sucampo Pharmaceuticals Announces Fourth Quarter And Full Year 2012 Financial Results And Operating Highlights Teleconference And Webcast - Business Wire 03.06.13 | 06:03 am
- Sucampo Appoints Barbara A. Munder And Maureen E. O’Connell To Board Of Directors - Business Wire 03.01.13 | 06:03 am
- Sucampo Announces Commercial Availability Of RESCULA In U.S. Pharmacies - Business Wire 02.19.13 | 08:02 pm
- Sucampo Files Patent Infringement Lawsuit Against Anchen Pharmaceuticals And Par Pharmaceuticals - Business Wire 02.08.13 | 06:02 am
- Sucampo Pharmaceuticals To Present At Investment Conferences - Business Wire 02.06.13 | 06:02 am
- Sucampo Announces Japanese Government Funding For Unoprostone Isopropyl Development In Retinitis Pigmentosa - Business Wire 02.04.13 | 06:02 am
- Sucampo Pharmaceuticals Announces Webcast Of Its Presentation At The Biotech ShowcaseTM 2013 Conference - Business Wire 01.03.13 | 06:01 am
- Sucampo Announces FDA Approval Of An SNDA For RESCULA® (unoprostone Isopropyl) - Business Wire 12.12.12 | 06:12 am
- Sucampo Receives $15 Million Milestone Payment From Abbott On First Sale Of AMITIZA® (lubiprostone) In Japan - Business Wire 12.11.12 | 06:12 am
Partner Headlines for SCMP
- 5 Pharmaceutical Companies With EMA Or MHRA Catalysts This Year - Seeking Alpha 08.28.12 | 09:08 am
- Phase 3 Long-Term Safety Trial Results of Lubiprostone in Patients with Irritable Bowel Syndrome with Constipation was Recently Published in Alimentary Pharmacology and Therapeutics - Benzinga 03.06.12 | 04:03 pm
- Life Sciences Companies Raise Record Amounts of Capital - Seeking Alpha 12.31.10 | 04:12 pm
